Skip to main content

Advertisement

Table 3 Offer of on-site HCV testing services among Opioid Treatment Programs offering any HCV testing (either on-site or off-site)

From: Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services

  (On-site vs. Off-site testing)
OR (95% CI)
Predictor variables  
 Director race/ethnicity 1†
  African-American 2.76 (1.03, 7.35)*
  Other race/ethnicity 0.66 (0.19, 2.27)
  White 1†
 Director age 0.97 (0.94, 1.00)^
 Director gender  
  Female 1.17 (0.65, 2.07)
  Male 1†
 Director education  
  Post-graduate training or more 1.04 (0.55, 1.95)
  College or less 1†
 Director sources of information 2.35 (1.39, 3.97)**
 Director support of preventive services 1.06 (0.78, 1.45)
Control variables  
Patient characteristics  
  Percent African-American patients 0.99 (0.97, 1.00)
  Percent Hispanic / Latino patients 1.01 (0.99, 1.02)
  Percent female patients 1.01 (0.99, 1.03)
  Percent persons who inject drugs 0.99 (0.98, 1.00)
Program characteristics  
  CARF accreditation  
   Yes 0.63 (0.31, 1.24)
   No 1†
  Ownership  
   Public 3.05 (1.20, 7.72)*
   Private for-profit 1.32 (0.62, 2.80)
   Private not-for-profit 1†
  Method of treatment  
   Both (Meth + Bup) 2.10 (0.98, 4.48)^
   Buprenorphine only (Bup) 0.14 (0.05, 0.33)***
   Methadone only (Meth) 1†
  Staff - patient ratio 1.70 (1.14, 2.54)*
  Prior authorization 1.00 (0.99, 1.01)
  Revenue from federal sources  
   At least 1% 1.97 (0.98, 3.90)*
   None 1†
  Revenue from private insurance  
   At least 1% 1.35 (0.70, 2.60)
   None 1†
  Year  
   2005 4.74 (2.45, 9.13)***
   2011 1†
  1. A total of 313 OTPs were included in the analysis
  2. Ninety-five percent confidence intervals estimated with robust standard errors
  3. † Reference category; OR, Odds ratio; CI, Confidence interval
  4. ^p< 0.10. *p < 0.05. **p < 0.01. ***p < 0.001